Collectively, these results demonstrated that PRKCQ-AS1 promotes tamoxifen resistance in ER + breast cancer cells through MKP1 upregulation and, targeting MKP1 may represent a potential therapeutic strategy to overcome PRKCQ-AS1-mediated tamoxifen resistance. Here, DUSP1 is linked to breast carcinoma.